Eli Lilly | LLY - Debt


Eli Lilly reported $54.91B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Abbott USD 34.05B 20.19B Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Amgen USD 57.3B 19M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Baxter International USD 9.67B 20M Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Drreddys Laboratories INR 72.29B 5.05B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
J&J USD 49.04B 5.95B Jun/2026
Medtronic USD 28.15B 192M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Neurocrine Biosciences USD 401.8M 4.4M Jun/2026
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 48.31B 1.31B Sep/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Perrigo USD 3.29B 337.7M Jun/2026
Pfizer USD 63.19B 536M Jun/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 2.07B 1.02B Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
Sanofi EUR 23.58B 3.56B Jun/2026
United Therapeutics USD 200M 100M Mar/2025
Zoetis USD 9.24B 0 Jun/2026